A groundbreaking review recently published in the Chinese Medical Journal, spearheaded by Professor Ajaikumar B. Kunnumakkara of the Indian Institute of Technology Guwahati and Assistant Professor Alan Prem Kumar from the National University of Singapore, casts a pioneering spotlight on nuclear receptors (NRs) as promising yet underutilized molecular switches in brain cancer biology. These ligand-activated transcription factors orchestrate broad transcriptional programs essential for cellular metabolism, immune regulation, and survival, yet their intricate roles in brain tumorigenesis and treatment evasion have remained largely enigmatic until now. The review meticulously dissects the regulatory networks influenced by NRs and proposes an integrated framework to leverage their therapeutic potential in combatting brain malignancies.

At the molecular level, nuclear receptors function as dynamic transcriptional regulators. They sense diverse endogenous ligands—ranging from steroid hormones to metabolic intermediates—and transduce these signals by binding specific DNA response elements, effectuating precise modulation of gene expression. Aberrant NR signaling rewires critical oncogenic pathways that underpin hallmark cancer traits including sustained proliferative signaling, resistance to cell death, invasion, and immune escape. Particularly in GBM, altered NR activity intersects with notorious pathways such as PI3K/Akt, NF-κB, EGFR, and Wnt/β-catenin, amplifying tumor aggressiveness and underpinning therapeutic resistance mechanisms.

The comprehensive analysis delineates several key nuclear receptor subtypes that play differential roles in glioma biology. Androgen receptors (ARs) have emerged as potent drivers of tumor survival and radioresistance, with preclinical data demonstrating that pharmacologic inhibition by agents like enzalutamide sensitizes GBM cells to irradiation and curtails proliferative capacity. Estrogen receptors (ERs), containing two major isoforms ERα and ERβ, exhibit context-dependent duality; while certain tumor microenvironments amplify ERβ’s tumor-suppressive effects, others may paradoxically harness ER signaling to facilitate glioma growth. Notably, tamoxifen, a selective estrogen receptor modulator, shows synergistic effects when paired with temozolomide chemotherapy, enhancing GBM cell apoptosis and attenuating tumor progression.

Glucocorticoid receptors (GRs) play a paradoxical role in brain cancer treatment paradigms. While dexamethasone and other glucocorticoids remain indispensable for mitigating peritumoral cerebral edema, chronic GR signaling is implicated in fostering an anti-apoptotic milieu that enhances tumor survival. This underscores the potential of GR antagonists like mifepristone as adjunct therapeutics that mitigate corticosteroid-induced tumor-supportive pathways without compromising neuroprotection. Liver X receptors (LXRs) present another intriguing therapeutic avenue; their activation by natural or synthetic agonists triggers cholesterol efflux and metabolic disruption in glioma cells, resulting in diminished tumor viability in rodent models.

Peroxisome proliferator-activated receptors (PPARs), particularly the gamma isoform (PPARγ), mediate intricate metabolic reprogramming and immunomodulatory effects within the tumor microenvironment. PPARγ agonists engage cellular apoptosis pathways and reduce inflammatory cytokine production, thereby degrading the protective niche that sustains glioma stem cells and facilitates tumor expansion. The review also shines a spotlight on orphan nuclear receptors, a subclass with no well-characterized endogenous ligands, such as TLX and members of the NR4A family. These receptors are frequently upregulated within glioma stem cell populations, sustaining their self-renewal and plasticity which critically underlie tumor recurrence and multidrug resistance. Targeting such orphan receptors may obstruct the roots of cancer persistence and immune evasion.

Importantly, the heterogeneity of nuclear receptor expression across glioma subtypes and individual patients suggests their utility as precision biomarkers. Expression profiling of NRs could enable stratification of patients likely to respond to NR-directed therapies, heralding a transformative shift from empirical to mechanism-guided treatment selection. The review advocates for combinational therapeutic strategies that integrate NR modulators with existing modalities—chemotherapy, radiotherapy, and burgeoning immunotherapies—to amplify efficacy and overcome monotherapy limitations.

Notwithstanding their theoretical appeal, the successful translation of NR-targeted agents confronts formidable obstacles, chief among them the impermeability of the blood-brain barrier (BBB). The BBB’s selective permeability restricts most pharmacological agents from attaining therapeutic concentrations within the central nervous system milieu. Addressing this challenge necessitates innovative drug delivery platforms that enhance brain penetration without incurring neurotoxicity. Nanoparticle-based carriers, focused ultrasound techniques, and receptor-mediated transcytosis pathways appear promising in circumventing this barrier to optimize NR ligand access to tumor loci.

Further, the fine-tuned regulation of nuclear receptors within complex intracellular milieus demands nuanced drug design to mitigate off-target effects and resistance evolution. Large-scale preclinical validation employing patient-derived xenografts and immunocompetent models is critical to assess safety, pharmacodynamics, and long-term outcomes of NR modulating compounds. Subsequently, rigorously designed clinical trials must clarify dose regimens, therapeutic windows, and synergistic potential with standard-of-care treatments. Gathering such data will be pivotal before nuclear receptor-based therapies can be seamlessly integrated into neuro-oncology treatment guidelines.

The insights articulated by this review underscore nuclear receptors as a largely untapped reservoir of therapeutic potential in brain cancer, offering avenues to modulate fundamental oncogenic switches. Targeting these receptors may disrupt biological pathways essential for tumor propagation, immune evasion, and treatment resistance, thereby redefining the therapeutic landscape for GBM and related gliomas. As Professor Kunnumakkara aptly summarizes, nuclear receptors embody a transformative frontier, ripe for exploration that could herald a paradigm shift in how devastating brain cancers are understood, prevented, and ultimately treated.

Emerging research along these lines promises to catalyze the development of bespoke molecular therapies tailored to the unique nuclear receptor profiles that distinguish and drive diverse brain tumor phenotypes. The integration of molecular biology, pharmacology, and cutting-edge delivery technologies envisioned in this roadmap offers a beacon of hope for significantly improving patient outcomes in a domain where the need for innovation has never been more acute. In battling one of humanity’s deadliest cancers, unlocking the therapeutic potential of nuclear receptors could mark a momentous stride towards durable remission and enhanced survival.

Subject of Research: Not applicable

Article Title: Unlocking therapeutic potential: Exploring nuclear receptors in brain cancer treatment

News Publication Date: 25-Aug-2025

Web References:

• https://journals.lww.com/cmj/fulltext/9900/unlocking_therapeutic_potential__exploring_nuclear.1713.aspx
• http://dx.doi.org/10.1097/CM9.0000000000003773

References:
10.1097/CM9.0000000000003773

Keywords:
Nuclear receptors, Proteins, Biomolecules, Receptor proteins, Medical treatments, Cancer treatments, Biochemistry, Biomedical engineering, Health care, Human health, Diseases and disorders

Glioblastoma treatment traditionally begins with maximal safe surgical resection, aiming to debulk the tumor mass and alleviate symptoms. Following this, patients undergo a regimen of radiotherapy combined with systemic chemotherapy, most commonly temozolomide monotherapy. However, this standard chemoradiation typically begins four to six weeks postoperative, introducing a therapeutic latency that may unintentionally empower residual glioma cells to repopulate the resection cavity and invade adjacent brain parenchyma. Such cellular behavior post-resection inherently restricts the overall efficacy of adjuvant therapies and calls for innovative approaches targeting these elusive perimarginal zones where microscopic disease seeds new tumor growth.

An emergent focal point in neuro-oncology research is the anatomical and biological characterization of the resection margin and surrounding peri-marginal zones as pivotal clinical targets. These regions harbor residual glioma stem-like cells exhibiting profound tumorigenic potential and profound resistance to conventional treatments. Recognizing the resection cavity and its interface with the infiltrated brain as a distinct microenvironment opens new therapeutic vistas. The challenge lies in delivering effective therapies locally and promptly to suppress residual malignant cells precisely where they reside, without systemic toxicity or delay.

In this context, locoregional therapeutic strategies are gaining traction as a compelling complement to systemic treatment. These approaches involve the direct application of therapeutic agents to the resection site during or immediately after surgery, minimizing the window in which tumor repopulation can occur and achieving higher localized drug concentrations. Recent innovations have focused on refining drug delivery systems capable of penetrating the complex brain extracellular matrix and selectively targeting residual tumor cells embedded within the margins.

Nanotechnology stands at the forefront of these locoregional strategies, offering a versatile platform for targeted drug delivery applications in glioblastoma treatment. Nanoparticles can be engineered to encapsulate chemotherapeutics, immunomodulators, or gene therapy constructs, facilitating sustained, controlled release profiles while evading rapid clearance. Moreover, nanoparticle systems can be functionalized with ligands recognizing tumor-specific markers, enhancing selective uptake by malignant cells and sparing normal neurons and glia. This precision targeting is particularly crucial given the brain’s sensitivity and the need to mitigate collateral damage.

Intriguingly, nanotechnological interventions could be integrated intraoperatively, enabling direct application into the resection cavity or impregnation into implantable matrices or hydrogels laid down during surgery. Such localized delivery not only circumvents the blood-brain barrier—a formidable obstacle for systemic chemotherapy—but also prophylactically addresses microscopic disease immediately following debulking. Advances in nanoparticle biocompatibility, biodegradation kinetics, and payload versatility have made this approach technically feasible and increasingly translatable.

Despite these promising prospects, significant translational barriers remain before locoregional nanotechnologies for glioblastoma can enter mainstream clinical practice. Among these, the heterogeneity of glioblastoma tumors, varying degrees of invasiveness, and intrinsic resistance mechanisms challenge the universality of any single nanomedicine formulation. Additionally, ensuring the safety of implanted or locally applied nanoparticles, understanding their pharmacodynamics in the complex brain milieu, and rigorously assessing their impact on neurocognitive function demand comprehensive preclinical and clinical evaluations.

Furthermore, the regulatory landscape surrounding nanomedicine introduces complexity, requiring robust manufacturing standards and validation of consistent therapeutic efficacy. Addressing these hurdles necessitates multidisciplinary collaboration among neurosurgeons, neuro-oncologists, material scientists, and pharmacologists. The development of advanced imaging modalities to delineate resection margins more accurately during surgery will also synergize with locoregional therapies, ensuring precise targeting and monitoring of treatment responses.

In parallel, ongoing research is exploring combinatorial nanotherapeutic regimens incorporating chemotherapeutic agents with radiosensitizers, immunostimulatory molecules, or RNA interference constructs aimed at oncogenic pathways. By tailoring the payload composition and release kinetics, it is envisioned that locoregional nanotechnology can orchestrate multifaceted attacks on residual tumor cells, addressing the heterogeneity and adaptability of glioblastoma.

Another critical aspect lies in understanding the immunological landscape of the glioblastoma microenvironment post-resection. Nanoparticles engineered to modulate the local immune response could potentiate anti-tumoral activity by activating resident microglia and infiltrating immune cells. Such immunomodulatory strategies may convert the resection margin from a sanctuary for tumor regrowth into a site of sustained immune surveillance and destruction.

The promise of these advanced locoregional nanotechnologies extends beyond glioblastoma, potentially informing treatment approaches for other infiltrative brain malignancies and metastases. Their modular design allows for adaptation to diverse therapeutic payloads and adjunctive treatments, paving the way for personalized neuro-oncological interventions.

As this nascent field progresses, the integration of real-time intraoperative imaging and novel targeting ligands could further refine nanoparticle localization. Emerging modalities like fluorescence-guided resection and intraoperative MRI combined with nanotechnology-infused therapies may revolutionize surgical oncology by enabling dynamic, precision-guided excisions coupled with immediate locoregional drug administration.

Ultimately, the translation of locoregional nanotechnologies from bench to bedside promises to redefine the therapeutic landscape for glioblastoma, converting an unmet clinical need into an opportunity for durable disease control. Overcoming the multifaceted barriers—biological, technological, and regulatory—will require concerted efforts, but the potential to improve survival and quality of life for patients facing this devastating diagnosis is a compelling incentive.

In conclusion, targeting the glioblastoma resection margin with nanotechnological solutions represents a paradigm shift in neuro-oncological practice, moving toward immediate, localized, and precise postoperative interventions. By bridging surgical excellence with cutting-edge material science, the future of glioblastoma treatment is poised at an exciting frontier, offering hope to patients and clinicians alike in the battle against one of the most formidable human cancers.

Subject of Research: Locoregional nanotechnological approaches to target the glioblastoma resection margin following surgical tumor removal.

Article Title: Targeting the glioblastoma resection margin with locoregional nanotechnologies.

Article References:
Kisby, T., Borst, G.R., Coope, D.J. et al. Targeting the glioblastoma resection margin with locoregional nanotechnologies. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01020-2

Image Credits: AI Generated